English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/215625
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


A Pool of Eight Virally Vectored African Swine Fever Antigens Protect Pigs against Fatal Disease

AuthorsGoatley, Lynnette C.; Reis, Ana Luisa; Portugal, Raquel; Goldswain, Hannah; Shimmon, Gareth L.; Hargreaves, Zoe; Ho, Chak-Sum; Montoya, María ; Sánchez-Cordón, Pedro J.; Taylor, Geraldine; Dixon, Linda K.; Netherton, Christopher L.
KeywordsAfrican swine fever virus
Modified vaccinia Ankara (MVA)
Issue Date2020
PublisherMultidisciplinary Digital Publishing Institute
CitationVaccines 8(2): 234 (2020)
AbstractClassical approaches to African swine fever virus (ASFV) vaccine development have not been successful; inactivated virus does not provide protection and use of live attenuated viruses generated by passage in tissue culture had a poor safety profile. Current African swine fever (ASF) vaccine research focuses on the development of modified live viruses by targeted gene deletion or subunit vaccines. The latter approach would be differentiation of vaccinated from infected animals (DIVA)-compliant, but information on which viral proteins to include in a subunit vaccine is lacking. Our previous work used DNA-prime/vaccinia-virus boost to screen 40 ASFV genes for immunogenicity, however this immunization regime did not protect animals after challenge. Here we describe the induction of both antigen and ASFV-specific antibody and cellular immune responses by different viral-vectored pools of antigens selected based on their immunogenicity in pigs. Immunization with one of these pools, comprising eight viral-vectored ASFV genes, protected 100% of pigs from fatal disease after challenge with a normally lethal dose of virulent ASFV. This data provide the basis for the further development of a subunit vaccine against this devastating disease.
Description© 2020 by the authors.
Publisher version (URL)https://doi.org/10.3390/vaccines8020234
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
Pool_Goatley_Art2020.pdf5,7 MBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.